A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sunovion
ClinicalTrials.gov Identifier:
NCT00685841
First received: May 23, 2008
Last updated: November 1, 2012
Last verified: November 2012
  Purpose

A 12 week study to investigate the safety and effectiveness of arformoterol given twice daily compared to placebo in subjects with COPD.


Condition Intervention Phase
COPD
Drug: Arformoterol tartrate inhalation solution
Drug: Salmeterol MDI
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group Study of (R,R)-Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:


Further study details as provided by Sunovion:

Primary Outcome Measures:
  • Percent change from study baseline FEV1 to the end of the dosing interval (12 hours post-second dose for the BID treatment arms and 24 hours post-dose for the QD treatment arm) [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time-normalized area under the percent change from visit pre-dose curve for FEV1 over 12 hours (nAUC0-12) [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ] [ Designated as safety issue: No ]
  • Peak percent of predicted FEV1 [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ] [ Designated as safety issue: No ]
  • Time-normalized area under the percent change from study baseline curve for FEV1 over 12 hours (nAUC0-12) [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ] [ Designated as safety issue: Yes ]
  • Time-normalized area under the percent change from study baseline curve for FEV1 over 24 hours (nAUC0-24) [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ] [ Designated as safety issue: No ]
  • Timepoint changes in FEV1 [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ] [ Designated as safety issue: No ]
  • Time to onset of response [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ] [ Designated as safety issue: No ]
  • Time to peak change in FEV1 [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ] [ Designated as safety issue: No ]
  • At-home and in-clinic peak expiratory flow rate (PEFR) [ Time Frame: Weeks -2, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 ] [ Designated as safety issue: No ]
  • Ipratropium bromide MDI use [ Time Frame: Weeks -2, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 ] [ Designated as safety issue: Yes ]
  • Racemic albuterol MDI use [ Time Frame: Weeks -2, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 ] [ Designated as safety issue: Yes ]
  • Exacerbations of COPD [ Time Frame: Weeks -2, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 ] [ Designated as safety issue: Yes ]
  • COPD symptom ratings (over 12 weeks of treatment) [ Time Frame: Weeks -2, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 ] [ Designated as safety issue: No ]
  • Relationship between plasma concentrations of (R,R) formoterol and selected pharmacodynamic parameters [ Time Frame: Weeks -2, 0, 3, 6, 9, 12 ] [ Designated as safety issue: No ]

Enrollment: 717
Study Start Date: February 2002
Study Completion Date: June 2003
Primary Completion Date: June 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Arformoterol 50 mcg QD and placebo MDI
Drug: Arformoterol tartrate inhalation solution
Arformoterol 50 mcg QD
Other Names:
  • (R,R-)formoterol
  • Brovana
Experimental: B
Arformoterol 25 mcg BID and placebo MDI
Drug: Arformoterol tartrate inhalation solution
Arformoterol 25 mcg BID
Other Names:
  • (R,R)-formoterol
  • Brovana
Experimental: C
Arformoterol 15 mcg BID and placebo MDI
Drug: Arformoterol tartrate inhalation solution
Arformoterol 15 mcg BID
Other Names:
  • (R,R)-formoterol
  • Brovana
Active Comparator: D
Salmeterol MDI 42 mcg BID and placebo inhalation solution
Drug: Salmeterol MDI
Salmeterol MDI 42 mcg BID
Other Name: Serevent
Placebo Comparator: E
Placebo BID MDI and inhalation solution
Drug: Placebo
Placebo BID MDI

Detailed Description:

This study is a double-blind, double-dummy, randomized, placebo- and active-controlled, multicenter, parallel-group study of adult subjects with a primary clinical diagnosis of COPD. Approximately 800 subjects were to be randomized in this study. Study participation consisted of a total of eight (8) study visits over approximately four (4) months for each subject. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

  Eligibility

Ages Eligible for Study:   35 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Subject may be male or female and must be aged less than or equal to 35 years on the day the informed consent is signed.
  • Female subjects greater than or equal to 65 years of age must have a serum pregnancy test conducted at Visit 1 and confirmed negative prior to randomization. Subjects of childbearing potential must be using an acceptable method of birth control.
  • Female subjects who are considered not of childbearing potential must be:

    • documented surgically sterile (defined as status post-hysterectomy or bilateral tubal ligation) OR
    • postmenopausal
  • Subject must have a primary diagnosis of COPD, which may include components of chronic bronchitis and/or emphysema. Diagnosis can be made during the screening process.
  • Subject must have a minimum smoking history of 15 pack-years (pack-years = the number of cigarette packs per day times the number of years).
  • Subject must have a chest x-ray that is consistent with the diagnosis of COPD (e.g., not diagnostic of pneumonia, other infection, atelectasis, or pneumothorax or other active/ongoing pulmonary conditions) and taken less than or equal to 3 months prior to study start. If there is no chest x-ray taken less than or equal to 3 months prior to study start, or if recent results are unavailable for review, a chest x-ray will be performed.
  • Subject must be able to complete all study questionnaires and logs reliably. Exclusion Criteria
  • Female subject who is pregnant or lactating.
  • Subject who has participated in an investigational drug study within 30 days prior to study start, or who is currently participating in another investigational drug study.
  • Subject whose schedule or travel prevents the completion of all required visits.
  • Subject who is scheduled for in-patient hospitalization, including elective surgery (in patient or out-patient) during the trial.
  • Subject with life-threatening/unstable respiratory status, including upper or lower respiratory tract infection, within the previous 30 days prior to study start.
  • Subject with a known history of asthma or any chronic respiratory disease (including a current history of sleep apnea) other than COPD (chronic bronchitis and/or emphysema).
  • Subject with a history of cancer except non-melanomatous skin cancer. Subjects with a history of cancer that is considered surgically cured and without a recurrence within the past 10 years may participate in the study. History of hematologic/lymphatic malignancy treated with chemotherapy or radiation is not allowed.
  • Subject with a history of lung resection of more than one full lobe.
  • Subject who requires continuous supplemental oxygen therapy (unless subject resides at elevation greater than or equal to 4,000 feet).
  • Subject who has had a change in dose or type of any medications for COPD within 14 days prior to the screening visit.
  • Subject with a known sensitivity to (R,R)-formoterol, ipratropium, salmeterol or albuterol or any of the excipients contained in any of these formulations.
  • Subject with a history of substance abuse or drug abuse within 12 months of study start, or with a positive urine drug screen at study start.
  • Subject using any prescription drug for which concomitant beta-agonist administration is contraindicated (e.g., beta-blockers).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00685841

  Show 52 Study Locations
Sponsors and Collaborators
Sunovion
  More Information

No publications provided

Responsible Party: Sunovion
ClinicalTrials.gov Identifier: NCT00685841     History of Changes
Other Study ID Numbers: 091-050
Study First Received: May 23, 2008
Last Updated: November 1, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Sunovion:
Chronic obstructive pulmonary disease

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases
Pharmaceutical Solutions
Formoterol
Salmeterol
Therapeutic Uses
Pharmacologic Actions
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 27, 2014